{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.26","upperLimit":"0.29","value":"0.02"},{"groupId":"OG001","lowerLimit":"-0.29","upperLimit":"0.29","value":"0.00"},{"groupId":"OG002","lowerLimit":"-0.12","upperLimit":"0.41","value":"0.16"},{"groupId":"OG003","lowerLimit":"-0.03","upperLimit":"0.49","value":"0.25"},{"groupId":"OG004","lowerLimit":"0.31","upperLimit":"0.71","value":"0.54"},{"groupId":"OG005","lowerLimit":"-0.30","upperLimit":"0.26","value":"-0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"55"},{"groupId":"OG005","value":"53"}],"units":"Participants"}],"title":"DXA BMD for L1-4 (Spearman's Rank Correlation Coefficient)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.20","upperLimit":"0.37","value":"0.09"},{"groupId":"OG001","lowerLimit":"-0.16","upperLimit":"0.41","value":"0.14"},{"groupId":"OG002","lowerLimit":"-0.17","upperLimit":"0.38","value":"0.11"},{"groupId":"OG003","lowerLimit":"-0.10","upperLimit":"0.44","value":"0.19"},{"groupId":"OG004","lowerLimit":"0.13","upperLimit":"0.61","value":"0.40"},{"groupId":"OG005","lowerLimit":"-0.19","upperLimit":"0.37","value":"0.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"53"},{"groupId":"OG005","value":"51"}],"units":"Participants"}],"title":"DXA BMD for Femoral Neck (Spearman's Rank Correlation Coefficient)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.52","upperLimit":"0.64","value":"0.09"},{"comment":"Insufficient number of paired baseline CTX-1 and novel MR ADC values to enable statistical detection of Spearman's Rank correlation coefficient","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"-0.06"},{"groupId":"OG002","lowerLimit":"-0.74","upperLimit":"0.37","value":"-0.27"},{"groupId":"OG003","lowerLimit":"-0.59","upperLimit":"0.58","value":"-0.01"},{"groupId":"OG004","lowerLimit":"-0.81","upperLimit":"0.21","value":"-0.42"},{"groupId":"OG005","lowerLimit":"-0.30","upperLimit":"0.26","value":"0.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"}],"units":"Participants"}],"title":"Novel MR ADC Measurement (Spearman's Rank Correlation Coefficient)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"55"},{"groupId":"OG005","value":"55"}],"units":"Participants"}],"description":"Primary Outcome 2: To assess whether the novel magnetic resonance (MR) protocol and exploratory bone turnover markers can improve quantification of bone loss in patients with myeloma (new, relapsed, smouldering) and Monoclonal Gammopathy Of Uncertain Significance (MGUS) at baseline assessment, compared to Dual-energy X-ray Absorptiometry (DXA) and established bone turnover markers alone.\n\nIn this particular section, in a pooled cohort of participants from Groups 1 and 2, Spearman's rank correlation coefficients were calculated between all baseline bone turnover biomarkers and:\n\n1. Baseline novel MR Apparent Diffusion Coefficient (ADC) measurements;\n2. Baseline DXA (Dual-energy X-ray Absorptiometry) BMD (Bone Mineral Density) at lumbar spine (L1-4);\n\n2\\) Baseline DXA (Dual-energy X-ray Absorptiometry) BMD (Bone Mineral Density) at femoral neck.","dispersionType":"95% Confidence Interval","groups":[{"description":"Baseline measurements of P1NP (Procollagen type 1 N-terminal Propeptide).","id":"OG000","title":"Baseline P1NP"},{"description":"Baseline measurements of CTX-1 (Type I Collagen Cross-Linked C-Telopeptide).","id":"OG001","title":"Baseline CTX-1"},{"description":"Baseline measurements of ALP (Alkaline Phosphatase).","id":"OG002","title":"Baseline ALP"},{"description":"Baseline measurements of DKK1 (Dickkopf WNT Signaling Pathway Inhibitor 1).","id":"OG003","title":"Baseline DKK1"},{"description":"Baseline measurements of sclerostin.","id":"OG004","title":"Baseline Sclerostin"},{"description":"Baseline measurements of the ratio between RANKL and OPG (osteoprotegerin).","id":"OG005","title":"Baseline RANKL:OPG"}],"paramType":"NUMBER","populationDescription":"Pooled population of participants from Groups 1 and 2. Where the numbers analysed are lower than the overall number of participants analysed, this reflects either failure of paired measurements for bone turnover marker and DXA and ADC, or that ADC measurements were not indicated because baseline novel MR scan did not show a lytic lesion.","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Primary Outcome 2: Quantifying Bone Loss [Correlations Between Bone Turnover Markers, DXA (Dual-energy X-ray Absorptiometry) and ADC (Apparent Diffusion Coefficient)]","type":"PRIMARY","unitOfMeasure":"Spearman's rank correlation coefficient"}